Pamela J Goodwin

List of Publications by Year
in descending order

191 papers	23,985 citations	13099 68 h-index	7518 151 g-index
198 all docs	198 docs citations	198 times ranked	23479 citing authors

#	Article	IF	Citations
1	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology, 2013, 24, 2206-2223.	1.2	2,805
2	Tailoring therapiesâ€"improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of Oncology, 2015, 26, 1533-1546.	1.2	1,449
3	20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. New England Journal of Medicine, 2017, 377, 1836-1846.	27.0	1,052
4	De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Annals of Oncology, 2017, 28, 1700-1712.	1.2	844
5	The Effect of Group Psychosocial Support on Survival in Metastatic Breast Cancer. New England Journal of Medicine, 2001, 345, 1719-1726.	27.0	819
6	Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study. Journal of Clinical Oncology, 2002, 20, 42-51.	1.6	798
7	Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis. Cancer Prevention Research, 2010, 3, 1451-1461.	1.5	783
8	Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study. Journal of Clinical Oncology, 2002, 20, 42-51.	1.6	543
9	Risk of Menopause During the First Year After Breast Cancer Diagnosis. Journal of Clinical Oncology, 1999, 17, 2365-2365.	1.6	503
10	Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet, The, 1994, 343, 886-889.	13.7	493
11	Prevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women With Breast Cancer. Journal of the National Cancer Institute, 1999, 91, 1241-1247.	6.3	363
12	Understanding the benefit of metformin use in cancer treatment. BMC Medicine, 2011, 9, 33.	5.5	324
13	Prognostic Effects of 25-Hydroxyvitamin D Levels in Early Breast Cancer. Journal of Clinical Oncology, 2009, 27, 3757-3763.	1.6	305
14	Metformin in cancer: translational challenges. Journal of Molecular Endocrinology, 2012, 48, R31-R43.	2.5	295
15	Adjuvant Treatment and Onset of Menopause Predict Weight Gain After Breast Cancer Diagnosis. Journal of Clinical Oncology, 1999, 17, 120-120.	1.6	278
16	Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Research and Treatment, 1998, 47, 111-120.	2.5	277
17	Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities. Journal of Clinical Oncology, 2016, 34, 4203-4216.	1.6	277
18	Second Malignant Neoplasms: Assessment and Strategies for Risk Reduction. Journal of Clinical Oncology, 2012, 30, 3734-3745.	1.6	263

#	Article	IF	Citations
19	The Role of Obesity in Cancer Survival and Recurrence. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1244-1259.	2.5	248
20	Insulin-Lowering Effects of Metformin in Women with Early Breast Cancer. Clinical Breast Cancer, 2008, 8, 501-505.	2.4	214
21	Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Research and Treatment, 2012, 135, 821-830.	2.5	213
22	Health-Related Quality-of-Life Measurement in Randomized Clinical Trials in Breast Cancer--Taking Stock. Journal of the National Cancer Institute, 2003, 95, 263-281.	6.3	210
23	Metformin in Breast Cancer: Time for Action. Journal of Clinical Oncology, 2009, 27, 3271-3273.	1.6	187
24	Insulin- and Obesity-Related Variables in Early-Stage Breast Cancer: Correlations and Time Course of Prognostic Associations. Journal of Clinical Oncology, 2012, 30, 164-171.	1.6	180
25	Past, Present, and Future Challenges in Breast Cancer Treatment. Journal of Clinical Oncology, 2014, 32, 1979-1986.	1.6	180
26	Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Research and Treatment, 2011, 126, 215-220.	2.5	170
27	Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Research and Treatment, 2012, 134, 769-781.	2.5	165
28	Impact of the Obesity Epidemic on Cancer. Annual Review of Medicine, 2015, 66, 281-296.	12.2	158
29	The impact of diabetes on survival following breast cancer. Breast Cancer Research and Treatment, 2008, 109, 389-395.	2.5	152
30	Body size and breast cancer prognosis: A critical review of the evidence. Breast Cancer Research and Treatment, 1990, 16, 205-214.	2.5	147
31	Randomized Trial of a Telephone-Based Weight Loss Intervention in Postmenopausal Women With Breast Cancer Receiving Letrozole: The LISA Trial. Journal of Clinical Oncology, 2014, 32, 2231-2239.	1.6	141
32	Breast Cancer Prognosis in BRCA1 and BRCA2 Mutation Carriers: An International Prospective Breast Cancer Family Registry Population-Based Cohort Study. Journal of Clinical Oncology, 2012, 30, 19-26.	1.6	134
33	Quality of Life in a Randomized Trial of Group Psychosocial Support in Metastatic Breast Cancer: Overall Effects of the Intervention and an Exploration of Missing Data. Journal of Clinical Oncology, 2003, 21, 1944-1951.	1.6	124
34	Validation of the european organization for research and treatment of cancer quality of life questionnaire (QLQ-C30) as a measure of psychosocial function in breast cancer patients. European Journal of Cancer, 1998, 34, 510-517.	2.8	119
35	Effect of Metformin vs Placebo on and Metabolic Factors in NCIC CTG MA.32. Journal of the National Cancer Institute, 2015, 107, djv006-djv006.	6.3	112
36	Physical Activity, Weight Control, and Breast Cancer Risk and Survival: Clinical Trial Rationale and Design Considerations. Journal of the National Cancer Institute, 2009, 101, 630-643.	6.3	110

#	Article	IF	Citations
37	Reliability and Validity of the Body Image after Breast Cancer Questionnaire. Breast Journal, 2006, 12, 221-232.	1.0	109
38	Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Research and Treatment, 2010, 119, 13-24.	2.5	109
39	Weight management and physical activity throughout the cancer care continuum. Ca-A Cancer Journal for Clinicians, 2018, 68, 64-89.	329.8	109
40	Multidisciplinary weight management in locoregional breast cancer: results of a phase II study. Breast Cancer Research and Treatment, 1998, 48, 53-64.	2.5	107
41	Multicenter, Randomized, Cross-Over Clinical Trial of Venlafaxine Versus Gabapentin for the Management of Hot Flashes in Breast Cancer Survivors. Journal of Clinical Oncology, 2010, 28, 5147-5152.	1.6	106
42	Metformin Pharmacokinetics in Mouse Tumors: Implications for Human Therapy. Cell Metabolism, 2016, 23, 567-568.	16.2	105
43	Quality of Life in Long-Term Breast Cancer Survivors. Journal of Clinical Oncology, 2013, 31, 3540-3548.	1.6	102
44	Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Research and Treatment, 2002, 74, 65-76.	2.5	98
45	Health-Related Quality of Life and Psychosocial Status in Breast Cancer Prognosis: Analysis of Multiple Variables. Journal of Clinical Oncology, 2004, 22, 4184-4192.	1.6	98
46	Frequency of p53 Mutations in Breast Carcinomas From Ashkenazi Jewish Carriers of BRCA1 Mutations. Journal of the National Cancer Institute, 1999, 91, 469-473.	6.3	94
47	Therapeutic options for the management of hot flashes in breast cancer survivors: An evidence-based review. Clinical Therapeutics, 2007, 29, 230-241.	2.5	94
48	Quality-of-Life Measurement in Randomized Clinical Trials in Breast Cancer: An Updated Systematic Review (2001â€“2009). Journal of the National Cancer Institute, 2011, 103, 178-231.	6.3	94
49	Diabetes mellitus and breast cancer: a retrospective population-based cohort study. Breast Cancer Research and Treatment, 2006, 98, 349-356.	2.5	93
50	Weight gain in women with localized breast cancer â€” a descriptive study. Breast Cancer Research and Treatment, 1988, 11, 59-66.	2.5	92
51	Breast Carcinomas Arising in Carriers of Mutations in BRCA1 or BRCA2: Are They Prognostically Different?. Journal of Clinical Oncology, 1999, 17, 3653-3663.	1.6	92
52	Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Research and Treatment, 2007, 106, 39-47.	2.5	92
53	Association Between Metformin Therapy and Mortality After Breast Cancer. Diabetes Care, 2013, 36, 3018-3026.	8.6	92
54	Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Research, 2015, 17, 32.	5.0	92

#	Article	IF	Citations
55	Second consensus on medical treatment of metastatic breast cancer. Annals of Oncology, 2007, 18, 215-225.	1.2	86
56	Three methods for minimally important difference: no relationship was found with the net proportion of patients improving. Journal of Clinical Epidemiology, 2007, 60, 448-455.	5.0	85
57	Diet and Breast Cancer: Evidence That Extremes in Diet Are Associated With Poor Survival. Journal of Clinical Oncology, 2003, 21, 2500-2507.	1.6	84
58	Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design. Npj Breast Cancer, 2017, 3, 37.	5.2	84
59	Breast Cancer Survivorship: Where Are We Today?. Advances in Experimental Medicine and Biology, 2015, 862, 1-8.	1.6	82
60	Effect of Metformin vs Placebo on Invasive Diseaseâ€“Free Survival in Patients With Breast Cancer. JAMA - Journal of the American Medical Association, 2022, 327, 1963.	7.4	81
61	Prognosis of Breast Cancer in Carriers ofBRCA1andBRCA2Mutations. New England Journal of Medicine, 2007, 357, 1555-1556.	27.0	79
62	High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. Breast Cancer Research and Treatment, 2009, 114, 517-525.	2.5	77
63	Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial. Breast Cancer Research and Treatment, 2015, 150, 149-155.	2.5	77
64	Association of Obesity-Related Metabolic Disruptions With Cancer Risk and Outcome. Journal of Clinical Oncology, 2016, 34, 4249-4255.	1.6	77
65	Is Leptin a Mediator of Adverse Prognostic Effects of Obesity in Breast Cancer?. Journal of Clinical Oncology, 2005, 23, 6037-6042.	1.6	76
66	A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. Breast, 2019, 48, 17-23.	2.2	73
67	Responsiveness to Change in Health-Related Quality of Life in a Randomized Clinical Trial: A Comparison of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) with Analogous Scales from the EORTC QLQ-C30 and a Trial Specific Module. Journal of Clinical Epidemiology, 1998, 51, 137-145.	5.0	72
68	Insulin in the Adjuvant Breast Cancer Setting: A Novel Therapeutic Target for Lifestyle and Pharmacologic Interventions?. Journal of Clinical Oncology, 2008, 26, 833-834.	1.6	72
69	Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 2013, 141, 331-339.	2.5	70
70	Increased prevalence of prior breast cancer in women with newly diagnosed diabetes. Breast Cancer Research and Treatment, 2006, 98, 303-309.	2.5	68
71	Obesity and insulin resistance in breast cancer â€“ Chemoprevention strategies with a focus on metformin. Breast, 2011, 20, S31-S35.	2.2	65
72	A scalable serology solution for profiling humoral immune responses to SARSâ€CoVâ€2 infection and vaccination. Clinical and Translational Immunology, 2022, 11, e1380.	3.8	65

#	Article	IF	Citations
73	MAMMOGRAPHIC PARENCHYMAL PATTERN AND BREAST CANCER RISK: A CRITICAL APPRAISAL OF THE EVIDENCE1. American Journal of Epidemiology, 1988, 127, 1097-1108.	3.4	63
74	Serum Lipids and Outcome of Early-stage Breast Cancer: Results of a Prospective Cohort Study. Breast Cancer Research and Treatment, 2005, 94, 135-144.	2.5	62
75	The Rationale and Foundations Of Group Psychotherapy for Women with Metastatic Breast Cancer. International Journal of Group Psychotherapy, 1998, 48, 245-273.	0.6	61
76	HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. Cancer, 2002, 95, 2068-2075.	4.1	61
77	The history and contemporary challenges of the US Food and Drug Administration. Clinical Therapeutics, 2007, 29, 1-16.	2.5	61
78	Convergent Discriminitive, and Predictive Validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Assessment and Comparison with Analogous Scales From the EORTC QLQ-C30 and a Trial-Specific Module. Journal of Clinical Epidemiology, 1999, 52, 653-666.	5.0	59
79	Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2002, 20, 1344-1352.	1.6	56
80	Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study. Breast Cancer Research and Treatment, 2007, 105, 69-80.	2.5	53
81	Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2002, 20, 1344-1352.	1.6	51
82	Insulinâ€“Insulin-Like Growth Factor Axis and Colon Cancer. Journal of Clinical Oncology, 2009, 27, 165-167.	1.6	51
83	25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. Breast Cancer Research and Treatment, 2012, 133, 1077-1088.	2.5	51
84	Past recreational physical activity, body size, and all-cause mortality following breast cancer diagnosis: results from the breast cancer family registry. Breast Cancer Research and Treatment, 2010, 123, 531-542.	2.5	50
85	Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology Statement. Journal of Clinical Oncology, 2015, 33, 3961-3967.	1.6	50
86	Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis. Journal of the National Cancer Institute, 2021, 113, 1465-1475.	6.3	50
87	Elevated levels of plasma triglycerides are associated with histologically defined piemenopausal breast cancer risk. Nutrition and Cancer, 1997, 27, 284-292.	2.0	48
88	Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2. Clinical Genetics, 2000, 57, 376-383.	2.0	42
89	Lessons learned from enrollment in the BEST studyâ€”A multicenter, randomized trial of group psychosocial support in metastatic breast cancer. Journal of Clinical Epidemiology, 2000, 53, 47-55.	5.0	42
90	Obesity and endocrine therapy: Host factors and breast cancer outcome. Breast, 2013, 22, S44-S47.	2.2	42

#	Article	IF	Citations
91	Randomized trial of group psychosocial support in metastatic breast cancer: the BEST study. Cancer Treatment Reviews, 1996, 22, 91-96.	7.7	40
92	Identification of Cancer Care and Protocol Characteristics Associated With Recruitment in Breast Cancer Clinical Trials. Journal of Clinical Oncology, 2008, 26, 4458-4465.	1.6	37
93	Vitamin D in Cancer Patients: Above All, Do No Harm. Journal of Clinical Oncology, 2009, 27, 2117-2119.	1.6	37
94	Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?. Breast Cancer Research and Treatment, 2009, 114, 387-389.	2.5	37
95	Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis. Breast Cancer Research and Treatment, 2010, 122, 647-659.	2.5	37
96	Consensus on Medical Treatment of Metastatic Breast Cancer. Breast Cancer Research and Treatment, 2003, 81, 1-7.	2.5	36
97	Support groups in advanced breast cancer. Cancer, 2005, 104, 2596-2601.	4.1	32
98	Economic Analysis of Psychosocial Group Therapy in Women with Metastatic Breast Cancer. Breast Cancer Research and Treatment, 2006, 100, 183-190.	2.5	32
99	Prediagnosis Reproductive Factors and All-Cause Mortality for Women with Breast Cancer in the Breast Cancer Family Registry. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1792-1797.	2.5	32
100	Obesity and Hormone Therapy in Breast Cancer: An Unfinished Puzzle. Journal of Clinical Oncology, 2010, 28, 3405-3407.	1.6	32
101	Cyclical mastopathy and premenopausal breast cancer risk. Breast Cancer Research and Treatment, 1995, 33, 63-73.	2.5	31
102	Journal of Clinical Oncology Update on Progress in Cancer Survivorship Care and Research. Journal of Clinical Oncology, 2012, 30, 3655-3656.	1.6	31
103	Factor analysis of the psychosocial items of the EORTC QLQ-C30 in metastatic breast cancer patients participating in a psychosocial intervention study. Quality of Life Research, 1999, 8, 311-317.	3.1	30
104	Intake of Phytoestrogen Foods and Supplements Among Women Recently Diagnosed With Breast Cancer in Ontario, Canada. Nutrition and Cancer, 2012, 64, 695-703.	2.0	30
105	Obesity and Cancer: Insights for Clinicians. Journal of Clinical Oncology, 2016, 34, 4197-4202.	1.6	29
106	Sexual health in long-term breast cancer survivors. Breast Cancer Research and Treatment, 2018, 172, 159-166.	2.5	29
107	Comorbidities and Their Management: Potential Impact on Breast Cancer Outcomes. Advances in Experimental Medicine and Biology, 2015, 862, 155-175.	1.6	28
108	Diabetes, Metformin, and Breast Cancer: Lilac Time?. Journal of Clinical Oncology, 2012, 30, 2812-2814.	1.6	27

#	Article	IF	Citations
109	Breast health and associated premenstrual symptoms in women with severe cyclic mastopathy. American Journal of Obstetrics and Gynecology, 1997, 176, 998-1005.	1.3	26
110	Elevated high-density lipoprotein cholesterol and dietary fat intake in women with cyclic mastopathy. American Journal of Obstetrics and Gynecology, 1998, 179, 430-437.	1.3	26
111	Evaluation of Treatment Benefit in Journal of Clinical Oncology. Journal of Clinical Oncology, 2013, 31, 1123-1124.	1.6	26
112	Pain in Patients With Cancer. Journal of Clinical Oncology, 2014, 32, 1637-1639.	1.6	26
113	The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer. Npj Breast Cancer, 2020, 6, 6.	5.2	26
114	Weight Gain in Early-Stage Breast Cancer: Where Do We Go From Here?. Journal of Clinical Oncology, 2001, 19, 2367-2369.	1.6	25
115	Modifiable Lifestyle Factors and Breast Cancer Outcomes: Current Controversies and Research Recommendations. Advances in Experimental Medicine and Biology, 2015, 862, 177-192.	1.6	25
116	Attitudes of Canadian Oncology Practitioners Toward Psychosocial Interventions in Clinical and Research Settings in Women With Breast Cancer. , 1997, 6, 178-189.		24
117	The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32. Journal of the National Cancer Institute, 2021, 113, 192-198.	6.3	24
118	Obesity, insulin resistance and breast cancer outcomes. Breast, 2015, 24, S56-S59.	2.2	23
119	Obesity and Breast Cancer Outcomes: How Much Evidence Is Needed to Change Practice?. Journal of Clinical Oncology, 2016, 34, 646-648.	1.6	22
120	Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis. BMC Cancer, 2007, 7, 99.	2.6	21
121	Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry. Breast Cancer Research and Treatment, 2009, 117, 167-176.	2.5	20
122	Host Factors and Cancer Outcome. Journal of Clinical Oncology, 2010, 28, 4019-4021.	1.6	20
123	NEW and RENEW: Building the Case for Weight Loss in Breast Cancer. Journal of Clinical Oncology, 2012, 30, 2294-2296.	1.6	20
124	Progesterone Exposure and Breast Cancer Risk. JAMA Oncology, 2015, 1, 283.	7.1	20
125	Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. Breast Cancer Research and Treatment, 2015, 150, 605-611.	2.5	19
126	Support Groups in Breast Cancer: When a Negative Result Is Positive. Journal of Clinical Oncology, 2004, 22, 4244-4246.	1.6	17

#	Article	IF	Citations
127	Cyclical mastopathy: A critical review of therapy. British Journal of Surgery, 2005, 75, 837-844.	0.3	17
128	Feasibility of a randomized controlled trial of vitamin D vs. placebo in women with recently diagnosed breast cancer. Breast Cancer Research and Treatment, 2012, 134, 759-767.	2.5	16
129	Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial. Npj Breast Cancer, 2021, 7, 74.	5.2	16
130	Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. Npj Breast Cancer, 2021, 7, 77.	5.2	16
131	The Importance of a Family History of Breast Cancer in Predicting the Presence of a BRCA Mutation. American Journal of Human Genetics, 1999, 65, 1776-1778.	6.2	15
132	Metabolic factors, anthropometric measures, diet, and physical activity in long-term breast cancer survivors: change from diagnosis and comparison to non-breast cancer controls. Breast Cancer Research and Treatment, 2017, 164, 451-460.	2.5	15
133	Toronto Workshop on Late Recurrence in Estrogen Receptorâ€“Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI Cancer Spectrum, 2019, 3, pkz050.	2.9	15
134	Commentary on: â€œEffect of obesity on survival in women with breast cancer: systematic review and meta-analysisâ€•(Melinda Protani, Michael Coory, Jennifer H. Martin). Breast Cancer Research and Treatment, 2010, 123, 637-640.	2.5	14
135	Crown-like structures in breast adipose tissue of breast cancer patients: associations with CD68 expression, obesity, metabolic factors and prognosis. Npj Breast Cancer, 2021, 7, 97.	5.2	14
136	Alcohol and breast cancer risk â€” putting the current controversy into perspective. Breast Cancer Research and Treatment, 1991, 19, 221-231.	2.5	13
137	Host-Related Factors in Breast Cancer: An Underappreciated Piece of the Puzzle?. Journal of Clinical Oncology, 2008, 26, 3299-3300.	1.6	13
138	Post-surgical highly sensitive C-reactive protein and prognosis in early-stage breast cancer. Breast Cancer Research and Treatment, 2013, 141, 485-493.	2.5	13
139	Host Factors and Risk of Breast Cancer Recurrence: Genetic, Epigenetic and Biologic Factors and Breast Cancer Outcomes. Advances in Experimental Medicine and Biology, 2015, 862, 143-153.	1.6	13
140	Economic factors in cancer palliationâ€”methodologic considerations. Cancer Treatment Reviews, 1993, 19, 59-65.	7.7	12
141	Management of familial breast cancer risk. Breast Cancer Research and Treatment, 2000, 62, 19-33.	2.5	12
142	Breast cancer survivors: Taking charge of lifestyle choices after treatment. European Journal of Oncology Nursing, 2011, 15, 250-253.	2.1	12
143	Reversible Ovarian Ablation or Chemotherapy: Are We Ready for Quality of Life to Guide Adjuvant Treatment Decisions in Breast Cancer?. Journal of Clinical Oncology, 2003, 21, 4474-4475.	1.6	11
144	Options for Preservation of Fertility in Women. New England Journal of Medicine, 2005, 353, 1418-1420.	27.0	11

#	Article	IF	Citations
145	Responsiveness to change to change due to supportive-expressive group therapy, improvement in mood and disease progression in women with metastatic breast cancer. Quality of Life Research, 2007, 16, 1007-1017.	3.1	11
146	To Your Health: How Does the Latest Research on Alcohol and Breast Cancer Inform Clinical Practice?. Journal of Clinical Oncology, 2013, 31, 1917-1919.	1.6	11
147	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI Cancer Spectrum, 2019, 3, pkz049.	2.9	11
148	Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer. JNCI Cancer Spectrum, 2018, 2, pky028.	2.9	10
149	Medical, Psychosocial, and Health-Related Quality of Life Issues in Breast Cancer Survivors. , 2007, , 122-144.		10
150	Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32. Breast Cancer Research and Treatment, 2017, 164, 371-378.	2.5	9
151	The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention. Obesity, 2022, 30, 28-38.	3.0	9
152	The fox guarding the clinical trial: internal vs. external validity in randomized studies. , 1999, 8, 275-275.		8
153	Economic Issues in Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 2000, Volume 21, 375-384.	2.1	8
154	Health-Related Quality of Life Measurement in Symptom Management Trials. Journal of the National Cancer Institute Monographs, 2007, 2007, 47-52.	2.1	8
155	The costs of cancer therapy. European Journal of Cancer & Clinical Oncology, 1990, 26, 223-225.	0.7	7
156	Normal Weight Adiposity and Postmenopausal Breast Cancer Risk. JAMA Oncology, 2019, 5, 150.	7.1	7
157	Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study. Npj Breast Cancer, 2020, 6, 22.	5.2	7
158	A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24Âh following adjuvant chemotherapy for breast cancer. Breast Cancer Research and Treatment, 2012, 136, 143-151.	2.5	6
159	Psychosocial Support for Women with Advanced Breast Cancer. Breast Cancer Research and Treatment, 2003, 81, 103-110.	2.5	5
160	Quality of life in breast cancer: what have we learned and where do we go from here?. , 2004, , 93-125.		5
161	Prognostic associations of plasma hepcidin in women with early breast cancer. Breast Cancer Research and Treatment, 2020, 184, 927-935.	2.5	5
162	Cancer Antigen 15-3/Mucin 1â€,Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo. JNCI Cancer Spectrum, 2021, 5, pkab066.	2.9	5

#	Article	IF	Citations
163	The Restaging of Responding Patients With Limited Small Cell Lung Cancer. Chest, 1993, 103, 1010-1016.	0.8	4
164	Abstract GS1-08: CCTGMA.32, a phase III randomized double-blind placebo controlled adjuvant trial of metformin (MET) vs placebo (PLAC) in early breast cancer (BC): Results of the primary efficacy analysis (clinical trials.gov NCT01101438). Cancer Research, 2022, 82, GS1-08-GS1-08.	0.9	4
165	Group support in breast cancer: realistic hope, realistic benefits. Expert Review of Anticancer Therapy, 2002, 2, 135-136.	2.4	3
166	Health-Related Quality of Life in Cancer Patientsâ€"More Answers but Many Questions Remain. Journal of the National Cancer Institute, 2009, 101, 838-839.	6.3	3
167	Tibolone: the risk is too high. Lancet Oncology, The, 2009, 10, 103-104.	10.7	3
168	Metabolic Syndrome, Insulin Resistance, and Inflammation in Breast Cancer: Impact on Prognosis and Adjuvant Interventions. Current Breast Cancer Reports, 2010, 2, 182-189.	1.0	3
169	Breast Cancer Chemoprevention Gets Personal. Journal of Clinical Oncology, 2011, 29, 2296-2298.	1.6	3
170	Attitudes of Canadian Oncology Practitioners Toward Psychosocial Interventions in Clinical and Research Settings in Women With Breast Cancer. Psycho-Oncology, 1997, 6, 178-189.	2.3	3
171	Hype versus Hope: Metformin and Vitamin D as Anticancer Agents. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e69-e74.	3.8	2
172	Twenty-Twenty Hindsight: An Adjuvant Breast Cancer Trial Through the Retrospectoscope. Journal of Clinical Oncology, 2014, 32, 2284-2286.	1.6	2
173	Obesity and breast cancer â€“ whatâ€™s new?. Expert Review of Endocrinology and Metabolism, 2017, 12, 35-43.	2.4	2
174	Novel Insights Into the Impact of Lifestyle-Based Weight Loss and Metformin on Obesity-Associated Biomarkers in Breast Cancer. Journal of the National Cancer Institute, 2018, 110, 1161-1162.	6.3	2
175	Can We Find the Positive in Negative Clinical Trials?. Journal of the National Cancer Institute, 2019, 111, 637-638.	6.3	2
176	Obesity and Breast Cancer: Expanding the Hypothesis Space. Journal of the National Cancer Institute, 2021, 113, 107-108.	6.3	2
177	Diabetes and Cancer: Unraveling the Complexity. Journal of the National Cancer Institute, 2021, 113, 347-348.	6.3	2
178	Reply to R.M. Memmott et al. Journal of Clinical Oncology, 2009, 27, e227-e227.	1.6	1
179	Reply to A. Vazquez-Martin et al. Journal of Clinical Oncology, 2009, 27, e210-e210.	1.6	1
180	Obesity and Insulin Resistance in Breast Cancer: Are Clinical Trials Needed?. Breast Diseases, 2012, 23, 310-313.	0.0	1

#	Article	IF	Citations
181	Moving forward with obesity research in breast cancer. Breast, 2017, 32, 225-226.	2.2	1
182	Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. ACP Journal Club, 2000, 132, 106.	0.1	1
183	QOL Measurement in Lung Cancer. Pharmacoeconomics, 1993, 3, 422-425.	3.3	0
184	Reply to C.M. Booth et al. Journal of Clinical Oncology, 2013, 31, 3300-3300.	1.6	0
185	Progesterone and Synthetic Progestin Controversiesâ€"Reply. JAMA Oncology, 2015, 1, 987.	7.1	0
186	Insulin Resistance: Clinical Implications for Cancer Treatment and Prevention. Energy Balance and Cancer, 2011, , 269-291.	0.2	0
187	The Futility of Futility Analyses in Adjuvant Trials in Hormone Receptor Positive Breast Cancer. Journal of the National Cancer Institute, 2022, , .	6.3	0
188	Mammography reduces long-term mortality for women aged 50 to 74 years. ACP Journal Club, 1995, 123, 34.	0.1	0
189	A benefits package for breast cancer includes selective screening, choice of surgery, adjuvant therapy, and no routine follow-up. ACP Journal Club, 1995, 123, 35.	0.1	0
190	Monounsaturated fat was associated with a decreased risk for breast cancer, and polyunsaturated fat showed an increased risk. ACP Journal Club, 1998, 129, 19.	0.1	0
191	Multilayer bandaging plus compression hosiery was better than hosiery alone for unilateral lymphedema of a limb. ACP Journal Club, 2001, 134, 56.	0.1	0